Quest Diagnostics DGX recently announced a collaboration with Ultima Genomics, the developer of the revolutionary new ultra-high throughput sequencing architecture. Through the collaboration, the ...

Quest Diagnostics (NYSE:DGX) and Ultima Genomics have entered into a collaboration that will use Ultima’s genomic sequencing technology and Quest’s Haystack solid-tumor minimal residual disease ...

At-home collection, one-day fecal immunochemical test that meets American Cancer Society guidelines and HEDIS quality measures for lower gastrointestinal bleeding screening programs A number of ...

Clinical Genomics and Quest Diagnostics extend collaboration to provide InSure® ONE™, a fecal immunochemical test for colorectal cancer screening programs A recent press release by Quest Diagnostics ...

SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced pharmacogenomic (PGx) laboratory test ...

Quest Diagnostics has introduced a new pharmacogenomic (PGx) laboratory testing service designed to assist healthcare providers in understanding their patients' genetic responses to specific ...

Quest Diagnostics can benefit from continued demand for specific diagnostic testing across a broad range of clinical areas.

Quest Diagnostics Incorporated DGX entered into a multi-pronged collaboration with Scipher Medicine intended to expand patient access to diagnostic services, advancing precision medicine for ...

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: Genomic Vision (Paris:GV) (FR0011799907 – GV), a company specializing in the development of diagnostic tests for the early detection of cancers and ...

* Under terms of collaboration, Quest Diagnostics has right to use instrument to create an additional laboratory-developed test for detection of mutations in BRCA gene, which can cause hereditary ...